Tonix Pharmaceuticals Holding CORP 8-K filings

Tonix Pharmaceuticals announced the discovery of novel oxytocin analogs that show promise for treating craniofacial pain and other conditions, with reduced dependence on magnesium.

Tonix Pharmaceuticals has selected two contract manufacturing organizations, including Almac Pharma Services, to support the potential launch and commercialization of its fibromyalgia drug, Tonmya.

Tonix Pharmaceuticals announced it will become a fully integrated pharmaceutical company on April 1, 2024, taking over commercial activities for its migraine products and preparing for the potential launch of Tonmya for fibromyalgia in 2025.

Tonix Pharmaceuticals reported additional positive efficacy data from its Phase 3 RESILIENT study, showing improvement in brain fog and other fibromyalgia symptoms with Tonmya.

Tonix Pharmaceuticals announced the publication of a research paper showing nominal improvement in PTSD symptoms and sleep quality with TNX-102 SL in military-related PTSD after four weeks of treatment.

Tonix Pharmaceuticals has engaged EVERSANA to support the launch strategy and commercial planning for its fibromyalgia drug candidate, Tonmya, in the U.S.

Tonix Pharmaceuticals' TNX-1500, an Fc-modified humanized anti-CD40L monoclonal antibody, shows promising pharmacokinetic properties in animal studies, suggesting a three-week half-life in humans and supporting monthly dosing.

Tonix Pharmaceuticals has completed the clinical stage of its Phase 1 trial for TNX-1500, an anti-CD40L monoclonal antibody, with topline results expected in the third quarter of 2024.

Tonix Pharmaceuticals reports successful pharmacokinetic bridging study results for Tonmya, supporting regulatory filings in Japan and China.

Tonix Pharmaceuticals shareholders approved the issuance of up to 162,162,162 shares related to outstanding warrants and a proposal to adjourn the special meeting if necessary.

Tonix Pharmaceuticals has partnered with Rho, Inc. to assist in the New Drug Application submission to the FDA for Tonmya, a potential treatment for fibromyalgia.

Tonix Pharmaceuticals has received FDA clearance for an investigator-initiated trial of TNX-102 SL to evaluate its effectiveness in reducing acute stress reaction and preventing stress disorders.

Tonix Pharmaceuticals announced research indicating that patients with pre-existing chronic overlapping pain conditions (COPCs) have an increased risk of developing Long COVID symptoms.

Tonix Pharmaceuticals announced that the FDA has conditionally accepted the trade name Tonmya for its TNX-102 SL product candidate intended for the management of fibromyalgia.

Tonix Pharmaceuticals has increased its authorized common stock from 160 million to 1 billion shares following shareholder approval at a special meeting.

Tonix Pharmaceuticals has reduced its workforce by 19 employees to prioritize the development of its TNX-102 SL drug for fibromyalgia.